Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs

Executive Summary

Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.

You may also be interested in...



New Price Helps Secure Funding For Rubraca In England

Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.

NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund

Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route. 

NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)

Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.

Related Content

Topics

UsernamePublicRestriction

Register

PS123216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel